BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases of stable disease, in 29 evaluable patients with metastatic pancreatic adenocarcinoma. Median overall survival (OS) for all 37 patients in the trial was 3.3 months with a six-month survival rate of 34.4%.

In a subgroup of patients who were receiving the combination as second-line treatment (n=17), BL-8040 plus Keytruda led to a median OS of 7.5 months with a six-month survival rate of 51.5%. Data were presented at the European Society for Medical Oncology meeting in Munich...